Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial

Publication | Open Access

DOI Full Paper Access

230

Citations

References

2021

Year

Scott A. Halperin, Lingyun Ye, Donna MacKinnon‐Cameron, Bruce R. Smith, Pedro Cahn, Guillermo M. Ruiz‐Palacios, Aamer Ikram, Fernando Laņas, M. Lourdes Guerrero, Sergio Raúl Muñoz Navarro,

The Lancet

VaccinationVaccine SafetyVaccine DevelopmentVaccine TrialVirologyAdenovirus Type 5Vaccine EfficacyMedicineFinal Efficacy AnalysisCovid-19Interim Safety Analysis